Article Text

other Versions

Daclizumab, a humanized monoclonal antibody to the interleukin-2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double-blind, placebo-controlled, dose- ranging trial

Statistics from

This is a PDF-only article. The first page of the PDF of this article appears below.

PDF extract preview

Review history and Supplementary material

  • Competing interests: GVA, WS, BF and PR are consultants for Protein Design Labs. GVA, WS, BF, BS, DS, PM, WP, FA, JV, GW, DG, RS, ST and PR have all received research support from Protein Design Labs. VV, DY and RS are employees of Protein Design Labs.

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.